Phase II ARRY-614 + nivolumab+ipilimumab (melanoma) for Head and Neck Squamous Cell Carcinoma
This trial is testing a new drug, ARRY-614, to see if it is safe and effective when used with either nivolumab or ipilimumab to treat advanced solid tumors.
- Solid Tumors
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Non-Small Cell Lung Cancer
- Kidney Cancer
2 Primary · 5 Secondary · Reporting Duration: Up to 48 months
5 Treatment Groups
Phase Ib ARRY-614 + nivolumab + ipilimumab
1 of 5
Phase Ib ARRY-614 + nivolumab
1 of 5
Phase II ARRY-614 + nivolumab + ipilimumab (RCC)
1 of 5
Phase II ARRY-614 + nivolumab + ipilimumab (melanoma)
1 of 5
Phase II ARRY-614 + nivolumab
1 of 5
144 Total Participants · 5 Treatment Groups
Primary Treatment: Phase II ARRY-614 + nivolumab+ipilimumab (melanoma) · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any prior examinations of the effects of a combination therapy of Phase II ARRY-614, nivolumab and ipilimumab for melanoma?
"Presently, there are 765 clinical trials for Phase II ARRY-614 + nivolumab+ipilimumab (melanoma) in progress with 86 of these at the final stage. Although a few of them take place in Pittsburgh, PA, 42707 other sites host studies about this medication." - Anonymous Online Contributor
Are volunteers being enrolled for this clinical research currently?
"As per the clinicaltrials.gov registry, this medical trial is currently in need of participants. The initial posting was made on June 11th 2020 and editted as recently as January 9th 2022." - Anonymous Online Contributor
What results are expected to arise from the investigation of this clinical trial?
"This 28-day clinical trial will be assessing the Objective Response rate of patients. Secondary objectives include measuring Overall Survival, Duration of Response and Progression Free Survival via RECIST v1.1 guidelines." - Anonymous Online Contributor
What is the current capacity of this research study?
"Affirmative. Clinicaltrials.gov reveals that this clinical examination, which was first published on June 11th 2020, is actively enrolling volunteers. Approximately 144 participants must be enrolled from just one medical site." - Anonymous Online Contributor
What primary purpose does the combination of ARRY-614, nivolumab and ipilimumab (melanoma) serve?
"Phase II ARRY-614 + nivolumab+ipilimumab (melanoma) has been successfully used to treat various conditions, including malignant neoplasms, unresectable melanoma and squamous cell carcinoma. It is especially effective for anti-angiogenic therapy." - Anonymous Online Contributor